Scrip Asks…What Does 2022 Hold For Biopharma? Part 2: Deal Making, M&A And Financial Markets

More M&A Expected As Biotech Valuations Decline

Following two record-breaking years for biotech fundraising, stock valuations are heading downwards. Biopharma executives and industry experts surveyed by Scrip anticipate big pharma executing more deals and acquisitions in 2022.

Scrip Asks, Part 2
• Source: Alamy

More from Scrip Asks

More from Scrip